Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed - As fire encroached, City of Hope prepared to evacuate its Duarte campus
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - NCCN publishes patient resource on genetic testing to guide patient decisionmaking
- After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency
- New colorectal cancer screening strategies must advance the standard of care